Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P; Terlipressin Study Group.

Gastroenterology. 2008 May;134(5):1360-8. doi: 10.1053/j.gastro.2008.02.014. Epub 2008 Feb 13.

2.

Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.

Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, Ganger D, Jamil K, Pappas SC; REVERSE Study Investigators.

Gastroenterology. 2016 Jun;150(7):1579-1589.e2. doi: 10.1053/j.gastro.2016.02.026. Epub 2016 Feb 16.

PMID:
26896734
3.

Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P; TAHRS Investigators.

Gastroenterology. 2008 May;134(5):1352-9. doi: 10.1053/j.gastro.2008.02.024. Epub 2008 Feb 14.

PMID:
18471512
4.

Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.

Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber P; Terlipressin Study Group.

J Hepatol. 2011 Aug;55(2):315-21. doi: 10.1016/j.jhep.2010.11.020. Epub 2010 Dec 15.

5.

Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.

Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK.

J Gastroenterol Hepatol. 2003 Feb;18(2):152-6.

PMID:
12542598
6.

An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.

Sharma P, Kumar A, Shrama BC, Sarin SK.

Am J Gastroenterol. 2008 Jul;103(7):1689-97. doi: 10.1111/j.1572-0241.2008.01828.x. Epub 2008 Jun 28.

PMID:
18557715
7.

Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.

Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barrière E, Lebrec D, Valla DC, Moreau R.

J Gastroenterol Hepatol. 2002 Aug;17(8):882-8.

PMID:
12164964
8.

Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.

Fabrizi F, Dixit V, Messa P, Martin P.

Int J Artif Organs. 2009 Mar;32(3):133-40. Review.

PMID:
19440988
9.

Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.

Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome.

Hepatology. 2015 Aug;62(2):567-74. doi: 10.1002/hep.27709. Epub 2015 Feb 13.

10.

Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.

Sagi SV, Mittal S, Kasturi KS, Sood GK.

J Gastroenterol Hepatol. 2010 May;25(5):880-5. doi: 10.1111/j.1440-1746.2009.06132.x. Epub 2010 Jan 14. Review.

PMID:
20074149
11.

Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study.

Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, Gola E, Morando F, Stanco M, Rosi S, Sticca A, Cillo U, Angeli P.

Hepatology. 2016 Mar;63(3):983-92. doi: 10.1002/hep.28396. Epub 2016 Feb 3.

PMID:
26659927
12.

Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.

Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF.

Eur J Gastroenterol Hepatol. 2002 Feb;14(2):153-8.

PMID:
11981339
13.

Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes.

Rodriguez E, Henrique Pereira G, Solà E, Elia C, Barreto R, Pose E, Colmenero J, Fernandez J, Navasa M, Arroyo V, Ginès P.

Liver Transpl. 2015 Nov;21(11):1347-54. doi: 10.1002/lt.24210.

14.

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.

Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J.

Hepatology. 2002 Oct;36(4 Pt 1):941-8.

PMID:
12297842
15.

Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.

von Kalckreuth V, Glowa F, Geibler M, Lohse AW, Denzer UW.

Z Gastroenterol. 2009 Jan;47(1):21-6. doi: 10.1055/s-0028-1109084. Epub 2009 Jan 20.

PMID:
19156588
16.

Terlipressin in hepatorenal syndrome: Evidence for present indications.

Rajekar H, Chawla Y.

J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:109-14. doi: 10.1111/j.1440-1746.2010.06583.x. Review.

PMID:
21199521
17.

Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.

Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF.

Gastroenterology. 2002 Apr;122(4):923-30.

PMID:
11910344
18.

Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.

Muñoz LE, Alcalá EG, Cordero P, Martínez MA, Vázquez NY, Galindo S, Mendoza E, Segura JJ.

Ann Hepatol. 2009 Jul-Sep;8(3):207-11.

PMID:
19841499
19.

Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: a meta-analysis.

Hiremath SB, Srinivas LD.

Indian J Pharmacol. 2013 Jan-Feb;45(1):54-60. doi: 10.4103/0253-7613.106436.

20.

Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.

Ghosh S, Choudhary NS, Sharma AK, Singh B, Kumar P, Agarwal R, Sharma N, Bhalla A, Chawla YK, Singh V.

Liver Int. 2013 Sep;33(8):1187-93. doi: 10.1111/liv.12179. Epub 2013 Apr 21.

PMID:
23601499

Supplemental Content

Support Center